Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk.

PURPOSE Women with a high breast cancer risk due to a familial predisposition may choose between preventive surgery and regular surveillance. The effectiveness of surveillance in high-risk women and especially BRCA1/2 mutation carriers is unknown. We present first results from a single large family cancer clinic. PATIENTS AND METHODS Women with breast cancer risk over 15% were examined by physical examination every 6 months and mammography every year. Detection rates and screening parameters were calculated for the total group and separately for different age and genetic risk groups. RESULTS At least one examination was performed in 1,198 women: 449 moderate and 621 high-risk women and 128 BRCA1/2 mutation carriers. Within a median follow-up of 3 years, 35 breast cancers were detected (four ductal carcinoma-in-situ; 31 invasive tumors); the average detection rate was 9.7 per 1,000. Detection rates (95% confidence interval) for moderate and high-risk women and BRCA1/2 carriers were 3.3 (1.1 to 8.6), 8.4 (5.4 to 13.2), and 33 (17 to 63) per 1,000 person-years, respectively. The ratio of observed cases versus breast cancers expected in an average-risk population of comparable age was 2.7, 7.0 and 23.7 respectively. Overall, node negativity was 65%; 34% of primary tumors were less than 10 mm; sensitivity was 74%. Results with respect to tumor stage and sensitivity were less favorable in BRCA1/2 carriers and in women under the age of 40. CONCLUSION It is possible to identify young women at high risk for breast cancer. The number of cancers detected was significantly greater than expected in an age-matched average-risk population and related to the risk category. Overall, screening parameters were comparable to population screening data, with less favorable results in the youngest age group (< 40) and BRCA1/2 carriers.

[1]  M Oudkerk,et al.  Earlier detection of breast cancer by surveillance of women at familial risk. , 2000, European journal of cancer.

[2]  J. Klijn,et al.  Survival in hereditary breast cancer associated with germline mutations of BRCA2. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Hendriks,et al.  © 1999 Cancer Research Campaign Article no. bjoc.1999.0786 Interval cancers in the Dutch breast cancer screening , 2022 .

[4]  H. Choo,et al.  Mammography in Asian patients with BRCA1 mutations , 1999, The Lancet.

[5]  M. Berer Mammography in Asian patients with BRCA1 mutations , 1999, The Lancet.

[6]  J. Chang-Claude,et al.  Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. , 1998, European journal of cancer.

[7]  S. Duffy,et al.  Efficacy of breast‐cancer screening for female relatives of breast‐cancer‐index cases: Taiwan multicentre cancer screening (TAMCAS) , 1998, International journal of cancer.

[8]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[9]  A. Howell,et al.  Screening by mammography, women with a family history of breast cancer. , 1998, European journal of cancer.

[10]  I. Ellis,et al.  Screening women aged less than 50 years with a family history of breast cancer. , 1998, European journal of cancer.

[11]  J. Elmore,et al.  Ten-year risk of false positive screening mammograms and clinical breast examinations. , 1998, The New England journal of medicine.

[12]  H. D. de Koning,et al.  Nation‐wide breast cancer screening in The Netherlands: Results of initial and subsequent screening 1990–1995 , 1998, International journal of cancer.

[13]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.

[14]  E. Franssen,et al.  Management of women at increased risk for breast cancer: preliminary results from a new program. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[15]  D. Stoppa-Lyonnet,et al.  Intraductal component and BRCA1 associated breast cancer , 1996, The Lancet.

[16]  K. Kerlikowske,et al.  Effect of age, breast density, and family history on the sensitivity of first screening mammography. , 1996, JAMA.

[17]  K. Heimdal,et al.  Inherited predisposition to breast carcinoma. Results of first round examination of 537 women at risk. , 1996, Anticancer research.

[18]  D. Birnbaum,et al.  Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. , 1996, Cancer research.

[19]  H. Collette,et al.  Age specific sensitivity and sojourn time in a breast cancer screening programme (DOM) in The Netherlands: a comparison of different methods. , 1996, Journal of epidemiology and community health.

[20]  H. Quist,et al.  Inherited breast carcinoma--prospective findings in 1,194 women at risk. , 1996, Acta oncologica.

[21]  L. Tabár,et al.  Efficacy of breast cancer screening by age. New results swedish two‐county trial , 1995, Cancer.

[22]  S. Rubin,et al.  Efficacy of screening mammography. A meta-analysis. , 1995, JAMA.

[23]  N. Risch,et al.  Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994 .

[24]  K. Kerlikowske,et al.  Positive predictive value of screening mammography by age and family history of breast cancer. , 1993, JAMA.

[25]  S Shapiro,et al.  Report of the International Workshop on Screening for Breast Cancer. , 1993, Journal of the National Cancer Institute.

[26]  W. Thompson,et al.  Relationship between breast histopathology and family history of breast cancer , 1993, Cancer.

[27]  N. Day,et al.  Breast cancer screening programmes: the development of a monitoring and evaluation system. , 1989, British Journal of Cancer.

[28]  N E Day,et al.  Estimating the sensitivity of a screening test. , 1985, Journal of epidemiology and community health.